Price Isn't Enough: Sandoz Hones Biosimilars Strategy With Lessons From Omnitrope

As FDA fleshes out the beginnings of a biosimilar regulatory pathway in the U.S., Novartis AG's generics business Sandoz is starting to draw important lessons in how to effectively commercialize copy-cat biologics.